查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496008

全球乳癌诊断市场 - 2024 年至 2029 年预测

Global Breast Cancer Diagnosis Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 133 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022 年乳癌诊断市值为 48.59 亿美元，预计复合年增长率为 7.92%，到 2029 年市场规模将达到 82.85 亿美元。

乳癌被定义为乳房组织的恶性，已成为全世界女性的主要癌症。医生会进行多项测试来诊断癌症的起始部位，并找出癌症是否扩散到身体的其他部位。预计乳癌市场在给定的预测期内将呈现强劲成长，这可归因于全球乳癌盛行率的上升。

此外，世界各地的政府和组织正在实施各种倡议，以提高人们对乳癌的认识并支持早期诊断，预计这将在预测期内推动市场成长。此外，混合成像技术的引入等技术进步预计也将推动未来几年的市场成长。

市场驱动因素：

  • 全球乳癌发生率上升预计将推动市场发展。

世界各地的乳癌病例不断增加，增加了对其诊断和治疗的需求。据世界卫生组织称，2020年将有230万名女性被诊断出患有乳癌，导致68.5万人死亡。此外，每年新患者数量超过了肺癌，占全球所有癌症患者的11.7%。

世界癌症研究基金会和世界卫生组织表示，2008年至2020年间，全球乳癌发生率增加了20%，死亡率增加了14%。预计未来几年乳癌病例也将急剧增加，这预计将推动预测期内乳癌诊断市场的成长。美国癌症协会估计，美国将诊断出 281,550 例新的女性侵袭性乳癌病例和 2,650 例男性新病例。此外，根据美国癌症协会的数据，预计 2021 年将有 44,000 人死亡，其中包括 43,600 名女性和 530 名男性。

  • 政府提高乳癌诊断率的措施导致市场成长激增。

世界各国政府都担心乳癌的持续传播，也会影响各国的经济健康。因此，各国政府正在推出新倡议，透过提高人们对该疾病的认识并提供早期诊断援助来应对乳癌发病率上升的问题。

澳洲政府负责实施“澳洲乳房筛检计划”，这是澳洲政府与州和领地政府之间的联合倡议。该计划旨在及早诊断乳癌并降低乳癌发病率和死亡率。 2021年5月，澳洲政府累计联邦预算超过1亿美元用于乳癌和子宫颈癌筛检计画。

2021年2月，欧盟委员会宣布了欧洲战胜癌症计划，旨在改善欧盟（EU）的癌症预防、治疗和护理。该计划的四个关键行动领域之一是确保到 2025 年，90% 符合乳癌筛检资格的欧盟人口（包括其他几种癌症类型）都能接受乳癌筛检，其目标包括：

世界各国政府也发起了各种其他倡议，预计将增加乳癌诊断，因此预计将在未来几年推动市场成长。

北美地区占据主要市场占有率。

从地理位置来看，由于乳癌发生率高，北美地区预计将占据较大的市场占有率。根据世界卫生组织统计，北美年龄标准化（全球）发生率为每10万人89.4例，仅次于澳洲和纽西兰以及西欧。

此外，高度发展的医疗保健系统和民众的高度意识是支持北美市场主导地位的其他一些重要因素。由于该地区乳癌发生率不断上升，以及各国政府为提高意识和早期发现乳癌而采取的各种倡议，预计亚太地区的乳癌发生率将显着增长。

主要进展

  • 2023 年 6 月 - 数位病理解决方案和临床人工智慧应用领域的全球领导者 Paige 推出了扩展版 Paige Breast Suite。该套件包括 Paige Breast Detect、Paige Breast Neoplasm、Paige Breast Mitosis、Paige Breast Lymph Node 和 HER2Complete，旨在提高乳癌诊断的效率和可靠性。该套件还包括一个由人工智慧驱动的有丝分裂计数工具，这是乳癌诊断的关键组成部分。 Paige 乳房检测和肿瘤允许病理学家优先考虑病例审查，并且达到临床级别并符合监管标准。
  • 2023 年 5 月 - 辉瑞和赛默飞世尔科技合作，为 30 多个国家的肺癌和乳癌患者提供基于次世代定序(NGS) 的检测。此次合作旨在提供更快的基因分析，帮助医疗保健专业人员为每位患者选择正确的治疗方法。 Thermo Fisher 将确定使用 NGS 技术的当地实验室，并确保它们拥有必要的基础设施、训练有素的员工和品管措施。
  • 2023 年 5 月 - Hologic 讚扬了 USPSTF 近期的乳癌筛检指南，并表示增加筛检机会对于早期发现和挽救生命至关重要。该公司对建议从 40 岁开始进行筛检的改变表示讚赏，因为大约 60,000 例乳癌是在 50 岁以下的女性中被诊断出来的。 Hologic 承认，黑人女性罹患进行性癌症的时间比白人女性年轻 40%，而且死于乳癌的可能性更高。
  • 2023 年 2 月 - HALO Precision Diagnostics 在其位于加州奇科的乳房护理中心推出了用于乳癌早期检测的 HALO PathWay(TM)。这种创新方法使用先进的成像、基于人群的分析和基因检测来提供个人化护理。它在美国尚属首创，旨在透过在可以进行微创治疗的第一或第二阶段检测疾病来拯救生命。 HALO 在南加州也拥有最先进的基因检测实验室。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球乳癌诊断市场：依诊断技术分类

  • 介绍
  • 影像
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 切片检查
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 临床检查
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球乳癌诊断市场：依癌症类型分类

  • 介绍
  • BRCA 乳癌
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • ER & PR 乳癌
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • HER2 乳癌
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • EGFR突变检测乳癌
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球乳癌诊断市场：依最终用户分类

  • 介绍
  • 医院和诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 癌症研究中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 诊断实验室
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球乳癌诊断市场：按地区

  • 介绍
  • 北美洲
    • 透过诊断技术
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 透过诊断技术
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 透过诊断技术
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 透过诊断技术
    • 按癌症类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 透过诊断技术
    • 按癌症类型
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Abbott
  • Hologic Inc.
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Koninklijke Philips NV
  • Siemens AG
  • Fujifilm Holdings Corporation
  • Myriad Genetics
  • Carestream Health
简介目录
Product Code: KSI061611916

The global breast cancer diagnosis market is evaluated at US$4.859 billion for 2022 and is projected to grow at a CAGR of 7.92% to reach a market size of US$8.285 billion by 2029.

Breast cancer is defined as a malignant tumor formed in the tissues of the breast and has emerged as the leading cancer among women across the globe. The doctors carry out several tests to diagnose the site of initiation as well as to know if the cancer has metastasized to other body parts or not. The breast cancer market is expected to show robust growth during the given forecast period, which may be attributed to the rising prevalence of breast cancer across the globe.

Furthermore, various initiatives are being implemented by governments and organizations worldwide to spread awareness and assist in the early diagnosis of breast cancer, which is anticipated to propel the market's growth during the forecast period. Technological advancements, such as the introduction of hybrid imaging techniques, are also expected to augment the market's growth in the coming years.

Market Drivers:

  • The rising prevalence of breast cancer worldwide is anticipated to drive the market.

The cases of breast cancer have been increasing constantly all over the globe, which has led to an increased need for its diagnosis and treatment. According to the WHO, 2.3 million females were diagnosed with breast cancer in 2020, with the number of deaths accounting for 685 thousand. Furthermore, it has surpassed lung cancer in terms of the number of new cases per year and accounts for 11.7% of the total cancer cases worldwide.

The World Cancer Research Fund International and the WHO state that the incidence of breast cancer has increased by 20% globally between 2008 and 2020, while mortality has increased by 14%. The cases of breast cancer are projected to continue surging in the coming years as well, which is anticipated to propel the global breast cancer diagnosis market growth during the forecast period. The American Cancer Society estimates that the number of newly diagnosed cases of invasive breast cancer in the United States will be 281,550 in women, and 2,650 cases will be diagnosed among men. Furthermore, as per the American Cancer Society, an estimated death of 44,000 people, including 43,600 women and 530 men, is projected to occur in the year 2021.

  • Government initiatives for increasing breast cancer diagnosis pose to surge in the market growth.

The governments of countries around the world have been concerned regarding the continuous spread of breast cancer, which can hurt a country's economic condition as well. As a result, governments are launching new initiatives to tackle the rising incidence of breast cancer by increasing awareness and providing aid for early diagnosis.

The Australian government runs the "BreastScreen Australia Program", a joint initiative of the Australian and state and territory governments. The program aims to diagnose breast cancer at an early stage and consequently reduce illness and death from breast cancer. In May 2021, the Australian government announced that its federal budget would include more than $100 million for breast and cervical cancer screening programs.

In February 2021, the European Commission presented its "Europe's Beating Cancer Plan", which aims to improve cancer prevention, treatment, and care in the European Union. One of the four key action areas of the plan includes the target of ensuring that 90% of the EU population who qualify for breast cancer screenings, among a few other cancer types, are offered screening by 2025.

Various other initiatives are being launched by governments worldwide that are anticipated to increase the diagnosis of breast cancer and, hence, are projected to propel the market growth in the coming years.

The North American region holds a significant market share.

Geographically, the North American region is anticipated to hold a significant market share owing to its high incidence rate of breast cancer. According to the WHO, North America has an age-standardized (world) incidence rate of 89.4 per 100,000, which is only behind "Australia & New Zealand" and "Western Europe".

Furthermore, a highly developed healthcare system and high awareness among the population are some of the other prominent factors behind the market dominance in North America. The Asia-Pacific region is anticipated to witness substantial growth due to the rising incidences of breast cancer in the region, coupled with various initiatives implemented by the governments to spread awareness and for early detection of breast cancer.

Key Developments:

  • June 2023- Paige, a global leader in digital pathology solutions and clinical AI applications, launched its expanded Paige Breast Suite. The suite included Paige Breast Detect, Paige Breast Neoplasm, Paige Breast Mitosis, Paige Breast Lymph Node, and HER2Complete, designed to improve diagnostic efficiency and confidence in breast cancer diagnosis. The suite also includes an AI-powered tool for mitotic counting, a critical element of breast cancer diagnosis. Paige Breast Detect and Neoplasm enable pathologists to prioritize the review of cases and is a clinical-grade and meets regulatory standards.
  • May 2023- Pfizer and Thermo Fisher Scientific partnered to enhance local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries. The collaboration aims to provide faster gene analysis, enabling healthcare providers to select the right therapy for each patient. Thermo Fisher identify local labs using NGS technology and ensure they have the necessary infrastructure, trained staff, and quality control measures. Pfizer explore affordable patient access and raise healthcare provider awareness about advanced testing benefits.
  • May 2023- Hologic praised the USPSTF's recent breast cancer screening guidelines, stating that increasing access to screening is crucial for early detection and saving lives. The company commends the change, recommending women begin screening at age 40, as approximately 60,000 breast cancers are diagnosed in women under 50. Hologic acknowledges that Black women are 40% more likely to develop aggressive cancers at younger ages and die from breast cancer than white women.
  • February 2023- HALO Precision Diagnostics introduced the HALO PathWay(TM) for early breast cancer detection at its Chico, California Breast Care Center. This innovative approach uses advanced imaging, population-based analytics, and genetic testing to provide personalized care. The first of its kind in the US, it aims to save lives by detecting disease in stage 1 or 2 when minimally invasive therapies are available. HALO also has a state-of-the-art genetic testing laboratory in southern California.

Market Segmentation:

By Diagnostic Techniques

  • Imaging
  • Biopsy
  • Laboratory Tests

By Cancer Type

  • BRCA Breast Cancer
  • ER & PR Breast Cancer
  • HER 2 Breast Cancer
  • EGFR Mutation Test Breast Cancer
  • Others

By End-User

  • Hospitals and Clinics
  • Cancer Research Centers
  • Diagnostic Laboratories
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Belgium
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY DIAGNOSTIC TECHNIQUES

  • 5.1. Introduction
  • 5.2. Imaging
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Biopsy
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Laboratory Tests
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY CANCER TYPE

  • 6.1. Introduction
  • 6.2. BRCA Breast Cancer
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. ER & PR Breast Cancer
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. HER 2 Breast Cancer
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. EGFR Mutation Test Breast Cancer
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Cancer Research Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Diagnostic Laboratories
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Diagnostic Techniques
    • 8.2.2. By Cancer Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Diagnostic Techniques
    • 8.3.2. By Cancer Type
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Diagnostic Techniques
    • 8.4.2. By Cancer Type
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Belgium
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Diagnostic Techniques
    • 8.5.2. By Cancer Type
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Diagnostic Techniques
    • 8.6.2. By Cancer Type
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Australia
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects
      • 8.6.4.9. New Zealand
        • 8.6.4.9.1. Market Opportunities and Trends
        • 8.6.4.9.2. Growth Prospects
      • 8.6.4.10. Others
        • 8.6.4.10.1. Market Opportunities and Trends
        • 8.6.4.10.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott
  • 10.2. Hologic Inc.
  • 10.3. F. Hoffmann-La Roche Ltd
  • 10.4. GE Healthcare
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Koninklijke Philips N.V.
  • 10.7. Siemens AG
  • 10.8. Fujifilm Holdings Corporation
  • 10.9. Myriad Genetics
  • 10.10. Carestream Health